相似文献
1
INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study.
J Infect Dis. 2016 Feb 15;213(4):574-8. doi: 10.1093/infdis/jiv453. Epub 2015 Sep 15.
2
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Lancet Respir Med. 2019 Nov;7(11):951-963. doi: 10.1016/S2213-2600(19)30253-X. Epub 2019 Sep 30.
3
Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
Viral Immunol. 2012 Dec;25(6):471-6. doi: 10.1089/vim.2012.0024. Epub 2012 Oct 12.
4
A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.
Vaccine. 2019 Feb 8;37(7):919-925. doi: 10.1016/j.vaccine.2019.01.007. Epub 2019 Jan 16.
5
Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Vaccine. 2013 May 1;31(19):2358-65. doi: 10.1016/j.vaccine.2013.03.008. Epub 2013 Mar 13.
6
Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.
7
Declining responsiveness to influenza vaccination with progression of human pregnancy.
Vaccine. 2018 Jul 25;36(31):4734-4741. doi: 10.1016/j.vaccine.2018.05.117. Epub 2018 Jun 22.
8
Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
Clin Infect Dis. 2023 Dec 15;77(12):1723-1732. doi: 10.1093/cid/ciad458.
9
Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
Hum Vaccin Immunother. 2018 Mar 4;14(3):579-586. doi: 10.1080/21645515.2017.1415683. Epub 2018 Feb 23.
10
Hemagglutination-Inhibition Antibodies and Protection against Influenza Elicited by Inactivated and Live Attenuated Vaccines in Children.
J Infect Dis. 2025 Feb 20;231(2):e308-e316. doi: 10.1093/infdis/jiae489.
引用本文的文献
1
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza.
JCI Insight. 2023 Jul 24;8(14):e167464. doi: 10.1172/jci.insight.167464.
2
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.
Hum Vaccin Immunother. 2022 Apr 29;18(2):1886560. doi: 10.1080/21645515.2021.1886560. Epub 2021 May 19.
3
Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.
Rev Med Virol. 2021 Nov;31(6):e2225. doi: 10.1002/rmv.2225. Epub 2021 Feb 23.
4
[Not Available].
CMAJ. 2020 Nov 23;192(47):E1559-E1570. doi: 10.1503/cmaj.200642-f.
5
Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis.
Int J Infect Dis. 2021 Jan;102:397-411. doi: 10.1016/j.ijid.2020.09.1443. Epub 2020 Sep 28.
6
Efficacy of convalescent plasma for the treatment of severe influenza.
Crit Care. 2020 Jul 29;24(1):469. doi: 10.1186/s13054-020-03189-7.
7
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.
CMAJ. 2020 Jul 6;192(27):E745-E755. doi: 10.1503/cmaj.200642. Epub 2020 May 22.
8
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Lancet Respir Med. 2019 Nov;7(11):951-963. doi: 10.1016/S2213-2600(19)30253-X. Epub 2019 Sep 30.
9
Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization.
Contemp Clin Trials Commun. 2019 Jun 21;15:100401. doi: 10.1016/j.conctc.2019.100401. eCollection 2019 Sep.
10
Antiviral Therapy for the Next Influenza Pandemic.
Trop Med Infect Dis. 2019 Apr 18;4(2):67. doi: 10.3390/tropicalmed4020067.
本文引用的文献
1
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
2
Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.
Chest. 2013 Aug;144(2):464-473. doi: 10.1378/chest.12-2907.
3
Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection.
J Infect Dis. 2011 Dec 15;204(12):1879-85. doi: 10.1093/infdis/jir661. Epub 2011 Oct 12.
4
Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.
Vaccine. 2011 Jul 22;29 Suppl 2(0 2):B56-62. doi: 10.1016/j.vaccine.2011.04.105.
5
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.
Clin Infect Dis. 2011 Feb 15;52(4):447-56. doi: 10.1093/cid/ciq106. Epub 2011 Jan 19.
6
Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.
MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62.
7
Critically ill patients with 2009 influenza A(H1N1) infection in Canada.
JAMA. 2009 Nov 4;302(17):1872-9. doi: 10.1001/jama.2009.1496. Epub 2009 Oct 12.
8
Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.
N Engl J Med. 2009 Aug 13;361(7):680-9. doi: 10.1056/NEJMoa0904252. Epub 2009 Jun 29.
9
Treatment with convalescent plasma for influenza A (H5N1) infection.
N Engl J Med. 2007 Oct 4;357(14):1450-1. doi: 10.1056/NEJMc070359.
10
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
Ann Intern Med. 2006 Oct 17;145(8):599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. Epub 2006 Aug 29.
Zotero 插件